Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Stock Market News for Apr 12, 2021
by Zacks Equity Research
Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
by Zacks Equity Research
The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
by Zacks Equity Research
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
by Zacks Equity Research
ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.
Higher-Than-Expected PPI in March
by Zacks Equity Research
Higher-Than-Expected PPI in March.
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.
PPI Doubles Month Over Month to 1.0%
by Mark Vickery
We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots
by Zacks Equity Research
European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.
Earnings Estimates Rising for Moderna (MRNA): Will It Gain?
by Zacks Equity Research
Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study
by Zacks Equity Research
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
Company News for Apr 7, 2021
by Zacks Equity Research
Companies in The News Are: ILMN, NVAX, MRNA, BP.
Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine
by Zacks Equity Research
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
5 Stocks With High Earnings Yield for Superior Returns
by Rimmi Singhi
Check out high earnings yield stocks including AA, USAK, GIII, MU and MRNA for a standout portfolio.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies
by Zacks Equity Research
Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $132.55, moving +1.22% from the previous trading session.
The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Netflix, PepsiCo, General Electric and Moderna
Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Top Research Reports for Comcast, Netflix & PepsiCo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Comcast Corporation (CMCSA), Netflix,Inc. (NFLX) and PepsiCo, Inc. (PEP).
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.